Back to results
US 2020/0368367 A1Published application
Cyclodextrin-Panobinostat Adduct
AssigneeMidatech Limited
InventorsTom Coulter, Stephen Damment, Alessandro Pace, Daniel Palmer
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeMidatech Limited
InventorsTom Coulter, Stephen Damment, Alessandro Pace, Daniel Palmer
Estimating the term…
The present invention provides a method for producing a cyclodextrin-panobinostat adduct, comprising: a) providing a first aqueous solution comprising a buffering agent, the solution having a pH in the range 2.0 to 4.0; b) dissolving panobinostat in said first aqueous solution to provide a second aqueous solution; and c) mixing said second aqueous solution comprising panobinostat with a third aqueous solution comprising a cyclodextrin to form a fourth aqueous solution comprising a cyclodextrin-panobinostat adduct. Also provided is an artificial cerebrospinal fluid (CSF) solution comprising the cyclodextrin-panobinostat adduct and medical uses of the cyclodextrin-panobinostat adduct, including in the treatment of brain tumours.
-40. (canceled)
A method of treatment of a brain tumour in a mammalian subject, comprising administering a therapeutically effective amount of a cyclodextrin-panobinostat adduct to a mammalian subject in need thereof.
The method according to claim 1, wherein the brain tumour comprises a glioma.
The method according to claim 2, wherein the glioma comprises Diffuse Intrinsic Pontine Glioma (DWG).
The method according to claim 1, wherein the method comprises administration via convection-enhanced delivery (CED).
The method according to claim 1, wherein the cyclodextrin-panobinostat adduct is dissolved in artificial cerebrospinal fluid (CSF).
The method according to claim 1, wherein the cyclodextrin-panobinostat adduct is 2-hydroxypropyl-β-cyclodextrin-panobinostat.
The method according to claim 1, wherein the cyclodextrin-panobinostat adduct is administered substantially free of dimethyl sulphoxide (DMSO).
The method according to claim 1, wherein the cyclodextrin-panobinostat is administered at a concentration of between 1 μM and 100 μM.
The method according to claim 1, wherein the subject is a human child under 10 years of age.
Dependencies are inferred from the claim text.